Compare Stocks: NRSN, ELTX, APLM, and TVGN

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
APLM Apollomics	$22.61 +0.4%	$21.55	$10.01 ▼ $42.12	$49.47M	1.53	8,508 shs	6,726 shs
ELTX Elicio Therapeutics	$1.89 +1.3%	$2.80	$1.71 ▼ $16.00	$49.02M	1.29	335,473 shs	689,737 shs
NRSN NeuroSense Therapeutics	$6.35 -5.5%	$9.64	$5.00 ▼ $26.64	$12.75M	1.6	24,634 shs	7,325 shs
TVGN Tevogen Bio	$7.81 +1.3%	$6.40	$3.64 ▼ $43.66	$50.20M	0.17	7,717 shs	20,472 shs

10 Best Stocks to Own - Fall 2026

Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Fall 2026, despite the economic uncertainty rattling markets right now. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
APLM Apollomics	-2.02%	-2.77%	-4.63%	+29.17%	+21.08%
ELTX Elicio Therapeutics	+1.34%	-7.80%	-39.62%	-50.91%	-83.35%
NRSN NeuroSense Therapeutics	-5.51%	-8.55%	-20.23%	-60.54%	-73.09%
TVGN Tevogen Bio	+1.30%	+6.11%	+21.65%	-17.44%	-81.40%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
APLM Apollomics	$22.61 +0.4%	$21.55	$10.01 ▼ $42.12	$49.47M	1.53	8,508 shs	6,726 shs
ELTX Elicio Therapeutics	$1.89 +1.3%	$2.80	$1.71 ▼ $16.00	$49.02M	1.29	335,473 shs	689,737 shs
NRSN NeuroSense Therapeutics	$6.35 -5.5%	$9.64	$5.00 ▼ $26.64	$12.75M	1.6	24,634 shs	7,325 shs
TVGN Tevogen Bio	$7.81 +1.3%	$6.40	$3.64 ▼ $43.66	$50.20M	0.17	7,717 shs	20,472 shs

10 Best Stocks to Own - Fall 2026

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
APLM Apollomics	-2.02%	-2.77%	-4.63%	+29.17%	+21.08%
ELTX Elicio Therapeutics	+1.34%	-7.80%	-39.62%	-50.91%	-83.35%
NRSN NeuroSense Therapeutics	-5.51%	-8.55%	-20.23%	-60.54%	-73.09%
TVGN Tevogen Bio	+1.30%	+6.11%	+21.65%	-17.44%	-81.40%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
APLM Apollomics	1.00	Sell	N/A	N/A
ELTX Elicio Therapeutics	2.50	Moderate Buy	$19.75	944.97% Upside
NRSN NeuroSense Therapeutics	2.67	Moderate Buy	$170.00	2,577.17% Upside
TVGN Tevogen Bio	1.50	Reduce	$100.00	1,180.41% Upside

Current Analyst Ratings Breakdown

Latest NRSN, ELTX, APLM, and TVGN Analyst Ratings

Date	Company	Brokerage	Action	Rating
9/17/2026	APLM Apollomics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
9/3/2026	NRSN NeuroSense Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy
9/1/2026	APLM Apollomics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/18/2026	ELTX Elicio Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/17/2026	APLM Apollomics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
7/30/2026	NRSN NeuroSense Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
7/29/2026	ELTX Elicio Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
7/28/2026	APLM Apollomics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
7/17/2026	TVGN Tevogen Bio	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
7/14/2026	ELTX Elicio Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
7/13/2026	APLM Apollomics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)

(Data available from 9/19/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
APLM Apollomics	$8.50M	5.85	N/A	N/A	($2.89) per share	-7.82
ELTX Elicio Therapeutics	N/A	N/A	N/A	N/A	$0.09 per share	N/A
NRSN NeuroSense Therapeutics	N/A	N/A	N/A	N/A	($0.96) per share	N/A
TVGN Tevogen Bio	N/A	N/A	N/A	N/A	($211.84) per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
APLM Apollomics	-$10.94M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	9/24/2026 (Estimated)
ELTX Elicio Therapeutics	-$39.57M	-$2.17	N/A	N/A	N/A	N/A	-1,266.43%	-139.94%	11/12/2026 (Estimated)
NRSN NeuroSense Therapeutics	-$11.12M	-$0.54	N/A	N/A	N/A	N/A	N/A	N/A	12/2/2026 (Estimated)
TVGN Tevogen Bio	-$26.27M	-$4.63	N/A	N/A	N/A	N/A	N/A	-468.32%	11/13/2026 (Estimated)

Latest NRSN, ELTX, APLM, and TVGN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
8/14/2026	Q2 2026	TVGN Tevogen Bio	-$2.53	-$1.52	+$1.01	-$1.52	N/A	N/A
8/13/2026	Q2 2026	ELTX Elicio Therapeutics	-$0.5375	-$0.43	+$0.1075	-$0.43	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
APLM Apollomics	N/A	N/A	N/A	N/A	N/A
ELTX Elicio Therapeutics	N/A	N/A	N/A	N/A	N/A
NRSN NeuroSense Therapeutics	N/A	N/A	N/A	N/A	N/A
TVGN Tevogen Bio	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
APLM Apollomics	N/A	0.96	0.96
ELTX Elicio Therapeutics	1.20	2.77	2.77
NRSN NeuroSense Therapeutics	N/A	0.31	0.31
TVGN Tevogen Bio	N/A	0.33	0.33

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
APLM Apollomics	19.13%
ELTX Elicio Therapeutics	35.03%
NRSN NeuroSense Therapeutics	1.04%
TVGN Tevogen Bio	N/A

Insider Ownership

Company	Insider Ownership
APLM Apollomics	N/A
ELTX Elicio Therapeutics	50.90%
NRSN NeuroSense Therapeutics	27.40%
TVGN Tevogen Bio	65.60%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
APLM Apollomics	15	2.20 million	N/A	Not Optionable
ELTX Elicio Therapeutics	N/A	26.28 million	12.90 million	Not Optionable
NRSN NeuroSense Therapeutics	16	1.90 million	1.38 million	Not Optionable
TVGN Tevogen Bio	3	6.51 million	2.24 million	N/A

NRSN, ELTX, APLM, and TVGN Headlines

Recent News About These Companies

Tevogen Bio Holdings Rebrands as Tevogen Inc.

July 30, 2026 | tipranks.com

Tevogen Bio Holdings Corporate Event Calendar | NASDAQ:TVGN

July 24, 2026 | benzinga.com

Tevogen Bio Announces 2026 Annual Meeting of Stockholders

July 13, 2026 | globenewswire.com

Tevogen Bio Inc: Tevogen Announces Formation of a Healthcare Services Initiative

June 10, 2026 | finanznachrichten.de

Tevogen Bio Holdings Inc. Announces William Keane as Interim Head of New Healthcare Services Initiative, Exploring MSO and CRO Acquisitions

June 9, 2026 | quiverquant.comQ

Tevogen Announces Formation of a Healthcare Services Initiative

June 9, 2026 | globenewswire.com

Tevogen Bio Inc: Tevogen Advances Strategic Acquisition Initiatives with Potential to Support Approximately $100 Million in Combined Annual Revenue

May 28, 2026 | finanznachrichten.de

Tevogen Advances Strategic Acquisition Initiatives with Potential to Support Approximately $100 ...

May 28, 2026 | enidnews.comE

Tevogen Advances Strategic Acquisition Initiatives with Potential to Support Approximately $100 Million in Combined Annual Revenue

May 28, 2026 | globenewswire.com

Tevogen Signs Letter of Intent to Evaluate Potential Acquisition of a Management Services ...

May 21, 2026 | caledonianrecord.comC

Tevogen Bio Holdings Inc. Signs Non-Binding Letter of Intent to Explore Strategic Healthcare Transaction

May 21, 2026 | quiverquant.comQ

Tevogen Signs Letter of Intent to Evaluate Potential Acquisition of a Management Services Organization

May 21, 2026 | globenewswire.com

Tevogen Bio Holdings Inc. Reports Significant Operational Improvements and Strategic Growth Initiatives

May 18, 2026 | quiverquant.comQ

Letter to Shareholders from CEO Dr. Ryan Saadi

May 18, 2026 | globenewswire.com

Tevogen Announces $3 Million Private Investment at $8 Per Share, a 14% Premium from Latest ...

May 12, 2026 | caledonianrecord.comC

Tevogen Bio Holdings Inc. Secures $3 Million PIPE Financing from The Patel Family, LLP

May 12, 2026 | quiverquant.comQ

Tevogen Announces $3 Million Private Investment at $8 Per Share, a 14% Premium from Latest Market Close

May 12, 2026 | globenewswire.com

Tevogen (TVGN) Soars 11% as Firm Gears Up for AI Training Commercialization

May 5, 2026 | finance.yahoo.com

Tevogen.AI Nears Completion of PredicTcell™ Training; Initiates Commercial Readiness and Debuts Internal Application Portal

April 27, 2026 | finance.yahoo.com

Tevogen.AI Nears Completion of PredicTcellâ„¢ Training; Initiates Commercial Readiness and Debuts Internal Application Portal

April 27, 2026 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

NRSN, ELTX, APLM, and TVGN Company Descriptions

Apollomics NASDAQ:APLM

$22.60 +0.09 (+0.38%)

Closing price 09/18/2026 03:59 PM Eastern

Extended Trading

$22.60 0.00 (0.00%)

As of 09/18/2026 07:30 PM Eastern

Apollomics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of oncology therapies to harness the immune system and target specific molecular pathways to eradicate cancer. The company's products portfolio includes Vebreltinib (APL-101), an oral active, highly selective c-Met inhibitor, which is in Phase 2 clinical trials for treatment of non-small cell lung cancer; APL-102, an oral active, small molecule Multiple Tyrosine Kinase Inhibitor, which is in a in a Phase 1 clinical trial to inhibit various kinases that are aberrantly activated in cancer cells; and APL-122, a tumor inhibitor candidate, targeting ErbB1/2/4 signaling pathwaysthat is in Phase 1 dose escalation clinical trials to treat cancers within the brain. Its also developing uproleselan (APL-106) that is in Phase 3 clinical trial for the treatment of adult patients with relapsed or refractory AML, as well as Phase 2/3 study with uproleselan for the treatment of newly diagnosed older adults with AML; and APL-108, a second-generation E-selective inhibitor, which has completed Phase 1 clinical trials to treat other liquid and solid cancers. The company's pipeline consists of preclinical stage immuno-oncology product candidates, such as APL-501, APL-502, APL-801 and APL-810. Its solutions include tumor inhibitors, anti-cancer enhancers, and immune-oncology drugs. Apollomics, Inc. was formerly known as CBT Pharmaceuticals, Inc. and changed its name to Apollomics, Inc. in January 2019. The company was incorporated in 2015 and is based in Foster City, California.

Elicio Therapeutics NASDAQ:ELTX

$1.89 +0.03 (+1.34%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$1.91 +0.02 (+1.06%)

As of 09/18/2026 04:53 PM Eastern

Angion Biomedica Corp. is a late-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of novel small molecule therapeutics to address acute organ injuries and fibrotic diseases. Angion Biomedica Corp. is based in UNIONDALE, N.Y.

NeuroSense Therapeutics NASDAQ:NRSN

$6.35 -0.37 (-5.51%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$6.36 +0.01 (+0.08%)

As of 09/18/2026 07:30 PM Eastern

NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases in the United States and internationally. The company's lead product is PrimeC, an extended-release oral formulation of a fixed-dose combination of ciprofloxacin and celecoxib, currently under Phase 2b/3 clinical trials for the treatment of amyotrophic lateral sclerosis, and completed Phase 2 clinical trials for the treatment of Alzheimer's, as well as under preclinical studies for the treatment of Parkinson's disease. Its preclinical pipeline includes StabiliC for the treatment of Parkinson's disease; and CogniC for the treatment of Alzheimer's disease. The company was incorporated in 2017 and is headquartered in Herzliya, Israel.

Tevogen Bio NASDAQ:TVGN

$7.81 +0.10 (+1.30%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$7.52 -0.29 (-3.71%)

As of 09/18/2026 05:49 PM Eastern

Tevogen Bio Holdings Inc. operates as a clinical-stage specialty immunotherapy company that develops off-the-shelf precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders. The company develops TVGN 489, which has completed Phase 1 clinical trial for the treatment and prevention of chronic lingering symptoms of the disease (Long COVID), as well as COVID-19 in B cell immune suppressed acute COVID-19 patients without a B cell cancer indication, elderly and infirm acute COVID-19 patients, and acute COVID-19 in patients on T cell suppressing drugs, including solid organ transplant patients. It is also developing TVGN 601 for treating multiple sclerosis; TVGN 930 for the treatment of Epstein-Barr virus associated lymphomas; TVGN 920 for treating cervical cancer; and TVGN 960 for the treatment of mouth and throat cancer. The company was founded in 2020 and is headquartered in Warren, New Jersey.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest NRSN, ELTX, APLM, and TVGN Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest NRSN, ELTX, APLM, and TVGN Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

NRSN, ELTX, APLM, and TVGN Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

NRSN, ELTX, APLM, and TVGN Company Descriptions

Apollomics NASDAQ:APLM

Elicio Therapeutics NASDAQ:ELTX

NeuroSense Therapeutics NASDAQ:NRSN

Tevogen Bio NASDAQ:TVGN

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest NRSN, ELTX, APLM, and TVGN Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest NRSN, ELTX, APLM, and TVGN Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

NRSN, ELTX, APLM, and TVGN Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

NRSN, ELTX, APLM, and TVGN Company Descriptions

Apollomics NASDAQ:APLM

Elicio Therapeutics NASDAQ:ELTX

NeuroSense Therapeutics NASDAQ:NRSN

Tevogen Bio NASDAQ:TVGN

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools